What caused the intraday drop in OBSN.SW stock?

No official press release matched the drop on 05 Feb 2026. The move likely reflects heavy selling, low float dynamics, or event-driven trading in a clinical-stage biotech. Check ObsEva news and regulatory filings for confirmation.

What is the current price and volume for OBSN.SW stock?

As of the intraday session on 05 Feb 2026 OBSN.SW stock traded at **CHF0.0012** with volume **2,351,202**, about **3.48x** the average volume of **675,842** shares.

What is Meyka AI’s rating and forecast for OBSN.SW stock?

Meyka AI rates OBSN.SW **58.59 (C+)** with a suggestion to HOLD. Meyka AI's forecast model projects a 12-month base target of **CHF0.0100** and a tactical target of **CHF0.0030**. Forecasts are projections, not guarantees.

Should investors expect dividends from ObsEva (OBSN.SW)?

ObsEva is a clinical-stage biotech and reports no dividend yield. The company reinvests cash into R&D, so dividend prospects are remote while clinical programmes continue.

CH Stocks

OBSN.SW stock drops 76.92% to CHF0.0012 on SIX intraday 05 Feb 2026: Liquidity watch

ByDanny Kontos February 5, 2026

OBSN.SW stock fell 76.92% intraday to CHF0.0012 on SIX on 05 Feb 2026, trading 2,351,202 shares versus an average of 675,842. The sharp drop followed heavy selling that pushed the day low to CHF0.0012 from an open of CHF0.005. Volume was 3.48x the average, signalling an unusually active session for this small-cap biotechnology name. For traders focused on most-active listings, ObsEva S.A. (OBSN.SW) pairs high intraday volatility with tight fundamentals and binary clinical risk.